RX Processing Corp’s CEO, Peter Fiorillo, is taking a bold step to advocate for the Dorgan-Snowe bill, legislation aimed at legalizing prescription drug importation into the United States. Fiorillo has launched a unique campaign, offering citizens a chance to win his first year’s salary, equivalent to 500,000 shares of company stock, currently valued at approximately $100,000, through a lottery.
Fiorillo’s initiative aims to highlight the grassroots movement, led by RX Processing Corp. and numerous others, pushing for the legalization of prescription drug importation to provide Americans with access to more affordable medication. RX Processing Corp. facilitates this by connecting Americans with licensed pharmacies, including a licensed Canadian pharmacy group, to obtain prescriptions from safe and cost-effective international suppliers.
The price discrepancy for prescription drugs between the U.S. and other countries, particularly Canada, is significant. Canada offers the same medications at substantially lower costs. Fiorillo emphasizes that Canadian drug safety standards meet or exceed those of the U.S. Food and Drug Administration (FDA).
Rising prescription drug costs are a growing concern in the U.S., disproportionately affecting senior citizens on fixed incomes and those lacking comprehensive prescription drug coverage. An estimated 43 million Americans are uninsured, and millions more have inadequate coverage, forcing difficult choices between essential medications and other necessities.
Currently, the FDA advises against importing prescription drugs, despite increasing public demand for it. The Dorgan-Snowe bill seeks to address this issue by permitting the importation of prescription drugs from Canada, where they are 30% to 80% cheaper. This move is expected to introduce competition and choice into the healthcare industry. The bill’s creation was fueled by mounting public pressure, with grassroots efforts, particularly within the senior community, playing a vital role in advancing the cause.